MED12 exon 2 mutations in histopathological uterine leiomyoma variants

European Journal of Human Genetics

Volumn 21, Issue 11, 2013, Pages 1300-1303

  Mäkinen, Netta ^a   Vahteristo, Pia ^a   Kämpjärvi, Kati ^a   Arola, Johanna ^a   Bützow, Ralf ^a   Aaltonen, Lauri A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

FH; MED12; uterine fibroid; uterine leiomyoma variants

Indexed keywords

FUMARATE HYDRATASE; MEDIATOR COMPLEX; MEDIATOR COMPLEX SUBUNIT 12; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CARCINOGENESIS; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEL MUTATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATION; MUTATION RATE; PRIORITY JOURNAL; UTERUS MYOMA;

DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; FUMARATE HYDRATASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEIOMYOMA; LOSS OF HETEROZYGOSITY; MEDIATOR COMPLEX; MUTATION; TISSUE BANKS; UTERINE NEOPLASMS;

EID: 84885898181     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.33     Document Type: Article

References (31)

1. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM: High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100-107. (Pubitemid 36135604)
2. Stewart EA: Uterine fibroids. Lancet 2001; 357: 293-298. (Pubitemid 32120866)
3. Flynn M, Jamison M, Datta S, Myers E: Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol 2006; 195: 955-964. (Pubitemid 44415640)
4. Hartmann KE, Birnbaum H, Ben-Hamadi R et al: Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol 2006; 108: 930-937. (Pubitemid 44498255)
5. Parker WH: Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 2007; 87: 725-736. (Pubitemid 46553757)
6. Hendrickson MR, Tavassoli FA, Kempson RL, McCluggage WG, Haller U, Kubik-Huch RA: Mesenchymal tumours and related lesions; in Tavassoli FA, Devilee P (eds). World Health Organization Classification of Tumours: Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003; pp 233-244.
7. Reed WB, Walker R, Horowitz R: Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol 1973; 53: 409-416.
8. Launonen V, Vierimaa O, Kiuru M et al: Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 2001; 98: 3387-3392. (Pubitemid 32220855)
9. Tomlinson IP, Alam NA, Rowan AJ et al: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30: 406-410.
10. Stewart L, Glenn GM, Stratton P et al: Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. Arch Dermatol 2008; 144: 1584-1592.
11. Kiuru M, Lehtonen R, Arola J et al: Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 2002; 62: 4554-4557.
12. Lehtonen R, Kiuru M, Vanharanta S et al: Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 2004; 164: 17-22. (Pubitemid 38364585)
13. Mäkinen N, Mehine M, Tolvanen J et al: MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011; 334: 252-255.
14. Taatjes DJ: The human Mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem Sci 2010; 35: 315-322.
15. Knuesel MT, Meyer KD, Donner AJ, Espinosa JM, Taatjes DJ: The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Mol Cell Biol 2009; 29: 650-661.
16. Kim S, Xu X, Hecht A, Boyer TG: Mediator is a transducer of Wnt/beta-catenin signaling. J Biol Chem 2006; 281: 14066-14075.
17. Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK et al: Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet 2006; 43: 523-526. (Pubitemid 43927328)
18. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-386.
19. Mäkinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, Aaltonen LA: MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget 2011; 2: 966-969.
20. Markowski DN, Bartnitzke S, Loning T, Drieschner N, Helmke BM, Bullerdiek J: MED12 mutations in uterine fibroids-their relationship to cytogenetic subgroups. Int J Cancer 2012; 131: 1528-1536.
21. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A: Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One 2012; 7: e33251.
22. Je EM, Kim MR, Min KO, Yoo NJ, Lee SH: Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer 2012; 131: E1044-E1047.
23. Perot G, Croce S, Ribeiro A et al: MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One 2012; 7: e40015.
24. Kämpjärvi K, Mäkinen N, Kilpivaara O et al: Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. Br J Cancer 2012; 107: 1761-1765.
25. Prayson RA, Hart WR: Mitotically active leiomyomas of the uterus. Am J Clin Pathol 1992; 97: 14-20.
26. Lehtonen HJ: Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam Cancer 2011; 10: 397-411.
27. Sanz-Ortega J, Vocke C, Stratton P, Linehan WM, Merino MJ: Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol 2013; 37: 74-80.
28. Wei MH, Toure O, Glenn GM et al: Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006; 43: 18-27. (Pubitemid 43099991)
29. Sandberg AA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma. Cancer Genet Cytogenet 2005; 158: 1-26. (Pubitemid 40354320)
30. Tallini G, Vanni R, Manfioletti G et al: HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest 2000; 80: 359-369. (Pubitemid 30167795)
31. Gross KL, Neskey DM, Manchanda N et al: HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies. Genes Chromosomes Cancer 2003; 38: 68-79. (Pubitemid 36994885)